Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.34) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ AMLX traded down $0.24 during mid-day trading on Wednesday, reaching $16.19. 131,566 shares of the company traded hands, compared to its average volume of 1,217,963. Amylyx Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $18.60. The firm has a market cap of $1.80 billion, a PE ratio of -10.47 and a beta of -0.11. The stock has a fifty day simple moving average of $15.30 and a 200-day simple moving average of $14.25.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. acquired a new position in shares of Amylyx Pharmaceuticals in the 4th quarter worth $25,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $28,000. Caitong International Asset Management Co. Ltd increased its stake in Amylyx Pharmaceuticals by 1,116.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock worth $54,000 after purchasing an additional 4,088 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares during the period. Finally, Legal & General Group Plc purchased a new stake in Amylyx Pharmaceuticals during the second quarter valued at about $47,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

AMLX has been the subject of a number of research reports. Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Bank of America upped their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. Mizuho lifted their target price on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Guggenheim boosted their price target on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Finally, Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.56.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.